AstraZeneca PLC Ebitda Over Time
| AZN Stock | USD 67.20 0.84 1.27% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out AstraZeneca PLC Performance and AstraZeneca PLC Correlation. AstraZeneca |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.034 | Dividend Share 2.97 | Earnings Share 2.08 | Revenue Per Share 2.7424 | Quarterly Revenue Growth 0.18 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare AstraZeneca PLC ADR and related stocks such as Novartis AG ADR, GlaxoSmithKline PLC ADR, and Roche Holding Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVS | 6.4 B | 17.3 B | 16.9 B | 16.4 B | 17.7 B | 14.4 B | 15 B | 15.9 B | 21.8 B | 15.6 B | 15.2 B | 17.1 B | 14.7 B | 18.3 B | 14 B |
| GSK | 661 M | 9.6 B | 8.6 B | 8.5 B | 5.7 B | 12.3 B | 4.5 B | 7.1 B | 7.4 B | 10.1 B | 8.1 B | 7.8 B | 8.6 B | 9.1 B | 6.4 B |
| BMY | 1.4 B | 7.1 B | 4.4 B | 3.2 B | 2.1 B | 2.4 B | 5.6 B | 5.7 B | 6.1 B | 6.6 B | 5 B | 20.2 B | 19.2 B | 19.4 B | 20.3 B |
| SNY | 1.2 B | 13 B | 12.9 B | 11.6 B | 10.2 B | 11.6 B | 11.1 B | 10.8 B | 11.2 B | 15.1 B | 17.9 B | 11.5 B | 14.3 B | 12.6 B | 11.3 B |
| MRK | 936.9 M | 9.8 B | 10.8 B | 8.3 B | 19.2 B | 8 B | 9 B | 8.3 B | 10.2 B | 12.9 B | 10.2 B | 17.9 B | 21.3 B | 6.9 B | 8.4 B |
| GILD | (4 M) | 3.9 B | 4 B | 4.5 B | 15.3 B | 22.3 B | 18.1 B | 14.6 B | 8.9 B | 6.2 B | 4.1 B | 11.3 B | 8.9 B | 7.6 B | 4.8 B |
| JNJ | 985.4 M | 19.5 B | 18.2 B | 19.5 B | 21.3 B | 19 B | 21.7 B | 19.8 B | 22.6 B | 22.1 B | 27.5 B | 30.9 B | 27.2 B | 29.3 B | 30.8 B |
| ABBV | 5.6 B | 4.9 B | 7 B | 6.6 B | 4.2 B | 8.4 B | 10.6 B | 11.1 B | 8.1 B | 13.8 B | 21.1 B | 28.3 B | 31.4 B | 17.3 B | 13.5 B |
| LLY | 820 M | 7.2 B | 4.5 B | 5.2 B | 4 B | 4.5 B | 4.3 B | 7.7 B | 9.6 B | 6.6 B | 8.9 B | 8 B | 8.7 B | 8.6 B | 5.2 B |
| PFE | 929.7 M | 29.2 B | 25 B | 21.9 B | 19.2 B | 17.7 B | 19.1 B | 20.2 B | 21.4 B | 19.7 B | 13.2 B | 30.8 B | 41 B | 9.6 B | 15.4 B |
| AMGN | 3.1 M | 5.1 B | 6.4 B | 6.3 B | 6.7 B | 9.1 B | 10.4 B | 10.9 B | 10.9 B | 10.4 B | 12.9 B | 12.5 B | 12.1 B | 7.9 B | 5.4 B |
AstraZeneca PLC ADR and related stocks such as Novartis AG ADR, GlaxoSmithKline PLC ADR, and Roche Holding Ebitda description
My Equities
My Current Equities and Potential Positions
Check out AstraZeneca PLC Performance and AstraZeneca PLC Correlation. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
AstraZeneca PLC technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.